Kristen Belmonte Slaoui Biography
Kristen Belmonte Slaoui is the Vice president & Business Development, Head (North America) at GlaxoSmithKline plc. She is also an adjunct assistant professor at The Johns Hopkins Bloomberg.
Kristen Belmonte Age
Kristen was born in July 1970.
Kristen Belmonte Slaoui Education
Kristen has a Bachelor’s degree in both Biology and Classical Studies from Gettysburg College. She earned a Ph.D. in Physiology from The Johns Hopkins Bloomberg School of Public Health. She completed an NIH Post-Doctoral Fellowship at the University of Washington.
Kristen Belmonte Slaoui GSK
Kristen is the Vice President and Head of Business Development at Tesaro Inc. The company was acquired by GSK in 2019. Tesaro, Inc. develops and commercializes cancer therapeutics and supportive care products. The Company offers receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.
Kristen first joined GSK after completing her fellowship at the University of Washington. She held a position in Respiratory Drug Discovery. Her work in pulmonary disease resulted in the discovery of the long-acting muscarinic receptor antagonist in the approved medicines.
In 2006 she joined the Business Development team and has since held various roles. She has spent nearly 20 years with GSK.
Kristen Belmonte Slaoui Husband
Kristen got married to Moncef Slaoui in March 2011 at the Lippincott House Bed and Breakfast off of Rittenhouse Square. It was a second marriage for both of them. Moncef Slaoui is a Morrocan-American immunologist who was appointed by President Donald Trump in May 2020 as the chief adviser of Operation Warp Speed, the government’s effort to speed up the development of a vaccine for the coronavirus.
He is a former chairman of GlaxoSmithKline (GSK) vaccines and Head of Pharmaceutical R&D. He also served as a member of Moderna’s Board of Directors since 2017 until May 2020. As an immunologist he is s credited for a cervical-cancer vaccine and a pneumococcal immunization. In 2015 he won European approval for the world’s first malaria vaccine.